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A Phase II Study of Paclitaxel  Etoposide  Cisplatin 
Concurrent Radiation Therapy for Previously Untreated
Limited Stage Small Cell Lung Cancer (E2596)
A Trial of the Eastern Cooperative Oncology Group
Leora Horn, MD,* Patricia Bernardo, ScD,† Alan Sandler, MD,* Henry Wagner, MD,‡
Nathan Levitan, MD,§ Mark L. Levitt, MD, PhD, and David H. Johnson, MD*
Introduction: To determine the 1-year survival, response rate, and
toxicity for patients with limited stage small cell lung cancer treated
with the combination of cisplatin plus etoposide plus paclitaxel with
delayed concurrent (starting with cycle 3) high dose thoracic radiotherapy.
Patients and Methods: Patients with previously untreated limited
stage small cell lung cancer, Easter Cooperative Oncology Group
performance status of 0–2 and adequate organ function were eligible.
Cycles 1 and 2 of chemotherapy consisted of paclitaxel 170 mg/m2
intravenous day 1, etoposide 80 mg/m2 intravenous days 1 to 3, and
cisplatin 60 mg/m2 intravenous day 1 followed by filgrastim 5 g/kg
subcutaneously days 4 to 13. Cycles 3 and 4 of chemotherapy consisted
of a reduced dose of paclitaxel 135 mg/m2 intravenous day 1, and the
same dose of etoposide and cisplatin with concurrent thoracic radiation
therapy 1.8 Gy in 35 fractions (total 63 Gy) administered over 7 weeks.
Results: Sixty-three patients were entered, 61 patients were eligible.
The most common grade 4 toxicity seen was granulocytopenia (62%).
Nonhematologic toxicities included febrile neutropenia in 19% of
patients, grade 3 and 4 esophagitis in 32% of patients, and grade 3
peripheral neuropathy in 14% of patients. Two patients suffered lethal
toxicities. The overall response rate was 79%. The 1-year survival rate
was 64%. The median overall survival was 15.7 months, and the
median progression-free survival was 8.6 months.
Conclusions: The combination of cisplatin plus etoposide plus pacli-
taxel chemotherapy and concurrent delayed thoracic radiotherapy as
administered in this trial provide no apparent advantage with respect to
response, local control, or survival compared with historical controls.
Key Words: Small cell lung cancer, Paclitaxel and etoposide-
cisplatin, Radiotherapy.
(J Thorac Oncol. 2009;4: 527–533)
An estimated 213,380 new cases of lung cancer will bediagnosed in the United States in 2008.1 Small cell lung
cancer (SCLC) will account for 12 to 15% of these cases.
Approximately one-third of patients with SCLC will present
with limited stage disease (LD). LD is defined as disease that
is confined to one hemi-thorax and its regional lymph nodes
that can be encompassed in a single radiotherapy port.2 SCLC
has been characterized as a chemotherapy sensitive neo-
plasm.3 A meta-analysis including 19 trials found platinum
based therapy to be more effective than nonplatinum combi-
nations.4 Cisplatin plus etoposide is the most frequently used
combination in North America and Europe.5–7 With the
advent of combined modality therapy with chemotherapy and
thoracic radiotherapy (TRT) the combination of cisplatin and
etoposide with TRT has been established as the standard
chemotherapy for LD-SCLC and has not changed in almost
two decades.8–14
The optimal timing and sequencing of TRT when
combined with chemotherapy remains controversial.15–18 A
possible advantage to beginning TRT after several cycles of
chemotherapy rather than at its outset derived from a reduc-
tion in the target volume thereby reducing the volume of
irradiated normal tissue (esophagus, spinal cord, normal lung,
and heart) which should reduce both acute and late toxicities
and facilitate radiation dose escalation. This approach has
been attempted and indicates local control and survival sim-
ilar to when TRT was begun on day 1 to the initial tumor
volume in some studies, although others found benefit for an
earlier start of TRT.19,20 The optimal dose and fractionation
of TRT are also not well defined. As small cell lung cancer is
sensitive to radiation, most trials have used moderate doses of
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TRT, single daily fractions of 1.8 to 2.5 Gy to total doses of
30 to 50 Gy with reported local failure rates of 30 to 50%.21
A retrospective analysis of patients with SCLC treated with
once-daily fractionation found improved local control rates as
the total dose delivered was increased from 30 to 50 Gy.22
Prospective attempts to improve local control by dose esca-
lation, at least in series using split course regimens have been
disappointing.23,24 A phase I study to determine the maximum
tolerated dose of once daily radiotherapy was conducted by
the Cancer and Leukemia Group B.25 The results of this trial
indicated that it is feasible to deliver once-daily TRT up to at
least 70 Gy administered concurrently with cisplatin-based
chemotherapy. It is hypothesized that this higher dose of once
daily radiotherapy may be equivalent or superior to the 45 Gy
twice-daily radiotherapy dose used in the last Intergroup
LD-SCLC trial.10
As the majority of patients with SCLC ultimately de-
velop metastatic disease, attempts have been made to im-
prove the efficacy of systemic chemotherapy. Two phase II
studies established the efficacy of single agent paclitaxel in
patients with SCLC, with response rates 43 to 68%.26,27 This
led to trials evaluating paclitaxel in several combinations
including with cisplatin and etoposide in patients with SCLC.
The University of Colorado Cancer Center conducted a phase
I/II trial in 28 patients with extensive disease-SCLC to
establish the optimal doses for paclitaxel combined with
cisplatin and etoposide (PET). The combination produced an
83% response rate and median survival of 10 months, there-
fore paclitaxel 175 mg/m2 intravenous, cisplatin 80 mg/m2
intravenous, and etoposide 80 mg/m2 on day 1 with oral
etoposide 160 mg/m2 on days 2 and 3 was the dose recom-
mended for phase II studies. The high rate of grade 4
neutropenia, seen in 82% of patients, has led to routine
administration of Granulocyte colony-stimulating factor on
days 4 to 14.28 Several phase II trials have evaluated the
combination of PET or carboplatin (CET) in patients with
LD- and extensive disease-SCLC with response rates ranging
from 45 to 98% and median survival of 7 to 18 months.29–34
TRT was administered to patients with LD after the comple-
tion of chemotherapy in these trials. One trial found patients
with Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) 2 experienced greater toxicities and death
and recommend only patients with PS 0–1 be enrolled in
further trials with this regimen.30
The improved response rates seen when paclitaxel has
been added to etoposide and cisplatin and in vitro data
indicating that paclitaxel is an effective radiosensitizer35,36
has led investigators to evaluate combination therapy with
PET plus TRT in the treatment of patients with LD-SCLC.
PET with concurrent chest radiotherapy was evaluated in a
phase I/II trial of 28 patients with LD-SCLC. Chemotherapy
consisted of paclitaxel 100 mg/m2 (with attempted dose
escalation to 135 and 170 mg/m2 as a phase I study) intra-
venous on day 1, etoposide 60 mg/m2 intravenous days 1 to
3, and cisplatin 60 mg/m2 intravenous on day 2 given con-
currently with radiotherapy (45 Gy in 25 fractions of 1.8 Gy
over 5 weeks). Cycles 3 and 4 of chemotherapy, given after
completion of radiotherapy, consisted of paclitaxel 170
mg/m2 intravenous on day 1 with Etoposide 80 mg/m2 intra-
venous on days 1 to 3 and cisplatin 60 mg/m2 intravenous on
day 2. Filgrastim 5 g/kg on days 5 to 14 was given with
cycles 3 and 4 only.37 The maximum tolerated dose of
paclitaxel with TRT was 135 mg/m2. Neutropenia was the
dose limiting toxicity. The overall response rate was 96%
including a 39% complete response rate. Two subsequent
phase II trials in patients with LD-SCLC reported similar
response rates with modest improvements in survival and
significant added toxicity and cost.38,39
Combining this novel three-drug regimen, PET with a
higher dose of concurrent TRT offered several potential
advantages: (1) Potential improvement in systemic control,
(2) Potential improvement in local control, and (3) By delay-
ing concurrent TRT to cycle 3 possible reduced toxicity as
compared with early concurrent chemoradiotherapy by using
the smaller ports associated with postinduction chemother-
apy. Thus, the Eastern Cooperative Oncology Group elected
to evaluate the combination of PET with delayed concurrent
TRT to the postchemotherapy volume in patients with previ-
ously untreated limited small cell lung cancer.
PATIENTS AND METHODS
Eligible patients had histologic (or cytologic) proof of
SCLC. Patients were clinically staged by radiologic exami-
nation of the head, chest, and abdomen as LD. Patients had to
have measurable or evaluable disease. Patients had to have
adequate hematologic, hepatic, and renal function as defined
as follows: white blood cell count 4000/mm3, platelets
100,000/mm3, creatinine 1.5 mg/dL, and total bilirubin
1.5 mg/dL, and a forced expiratory volume in 1 second 1
liter. Additional eligibility criteria included age 18 years
and an ECOG PS of 0–2. Patients may not have had prior
chemotherapy, radiation therapy, or biologic therapy for lung
cancer. Ineligible patients included those with pericardial or
pleural effusions with the exception of small effusions seen
only on computed tomography scan or effusions appearing
after invasive biopsy procedures. Patients with evidence of
symptomatic heart disease including angina, uncontrolled
congestive heart failure, uncontrolled arrhythmia, or a myo-
cardial infarction within 6 months were also ineligible. Pa-
tients had to have been disease-free for 5 years if they had
a history of prior malignancies (except for cured basal or
squamous cell skin cancers, or carcinoma in situ of the
cervix). Pregnant or lactating women were ineligible. All
patients provided written informed consent.
Patients received four cycles of PET with delayed
concurrent radiation therapy. Specifically, for cycles 1 and 2,
patients received paclitaxel 170 mg/m2 intravenous day 1,
etoposide 80 mg/m2 intravenous day 1 to 3, and cisplatin 60
mg/m2 intravenous day 2 every 21 days followed by filgras-
tim 5 g/kg subcutaneously on days 4 to 13 or until postnadir
white blood cell 10,000. During cycles 3 and 4 of chemo-
therapy, patients received paclitaxel 135 mg/m2 intravenous
day 1, etoposide 60 mg/m2 intravenous day 1 to 3, and
cisplatin 60 mg/m2 intravenous day 2 every 21 days with
concurrent TRT.
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Thoracic radiation began within 24 hours of the start of
cycle 3 day 1 (study day 43). Radiation therapy was given
with megavoltage therapy, with minimum peak energy of 4
MV with minimum source to isocenter distance of 100 cm.
Electron beams, 60Co, and 80 cm SSD treatment were not
acceptable. When possible, energies in excess of 15 MV were
avoided due to uncertainties in electron buildup but this may
not have been possible in those facilities which had only 6
and 20 Mv beams available. All patients underwent simula-
tion on a diagnostic quality unit before beginning chemother-
apy. Two target volumes (TV) were used in this treatment
regimen. The first, TV1, included the mediastinum from the
thoracic inlet to the subcarinal space, ipsilateral hilum, and
ipsilateral supraclavicular fossa in cases where there were
enlarged (1.5 cm) upper mediastinal lymph nodes, as well
as the prechemotherapy tumor volume with a margin of 1.5 to
2.0 cm. This volume was treated with the initial 45 Gy, in 25
fractions over 5 weeks at 1.8 Gy per fraction. TV2, which
was treated for the final 18 Gy, did include only the computed
tomography demonstrated tumor volume (primary and nodal)
remaining after the initial two cycles of chemotherapy with a
1.5 cm margin. TV2 was used to deliver the final 18 Gy in 10
fractions, over 2 weeks at 1.8 Gy per fraction. The total dose
was 63 Gy in 35 fractions at 1.8 Gy per fraction in 7 weeks.
Prophylactic cranial irradiation was administered to
patients at the discretion of the patient’s treating physicians.
This study was designed to have 86% power to detect
a 15% improvement in the 1-year survival rate, i.e., from 70
to 85%, for a one-sided 0.05-level test.40 The null hypothesis
of 70% survival at 1 year was rejected if we observed at least
45 survivors at 1 year. Confidence intervals for the proportion
of patients alive at 1 year and for response rates were
estimated using exact binomial confidence intervals.41 Sur-
vival curves were estimated by the method of Kaplan-
Meier.42 The primary end point for this study was the pro-
portion of patients alive at 1 year. Secondary endpoints were
objective overall response rate, with response assessed ac-
cording to the ECOG Solid Tumor Response Criteria, and
toxicity. Overall survival was defined as time from registra-
tion to death. Progression-free survival (PFS) was defined as
time from registration to tumor progression or death without
documented disease progression. Patients alive without pro-
gression were censored at the last time known to be in
remission or stable. Patients unevaluable for response were
censored at time zero.
To determine if prophylactic cranial irradiation (PCI)
treatment was associated with the site of relapse/progression
(both local and distant) at the time of relapse/progression,
two-sided 0.05-level Fisher’s exact test tests was performed.
Furthermore, a two-sided 0.05-level log-rank test was con-
ducted to determine if a difference in the time to progression
in (central nervous system) CNS existed between patients
who received PCI and those who did not. All patients who did
not develop CNS progression at the time of first relapse/
progression were censored at their initial relapse/progression
time (if they relapsed/progressed) or at their death date or the
last date they were known to be alive. Ineligible patients were
excluded from all analyses except for the toxicity analysis.
RESULTS
From December 1997 to October 1998, 63 patients
were accrued, of which 61 were eligible for enrollment. Two
patients were ineligible; one patient had an forced expiratory
volume in 1 second level 1.0 liter and another patient was
taken off study after cycle 2 because of suspected extensive
stage disease. The baseline characteristics of the 61 eligible
subjects are described in Table 1. The median age of patients
was 63 years (range 36–84 years); 43% were PS 0 and 57%
were PS 1; 26% of the patients had 5% weight loss in the
previous 6 months.
Toxicities
Toxicity data for all 63 patients are presented in Table
2. Forty-three patients suffered at least one grade 4 toxicity.
Hematologic toxicities were most frequent with grade 4
neutropenia occurring in 62%, grade 3 or 4 thrombocytopenia
in 8% and grade 3 anemia in 14% of patients. Febrile
neutropenia occurred in 19% of patients. Among the nonhe-
matologic toxicities, grade 3 or 4 esophagitis was seen in
32% of patients and grade 3 peripheral neuropathy in 14% of
patients. Two patients suffered treatment-related lethal tox-
icities; one patient died due to pulmonary failure, and one
patient died of treatment-related septic shock.
Response
Responses were assessed by the individual investiga-
tors. The overall response rate was 78.7%, (95% CI: 66.3–
88.2%) including 19.7% complete responses. Seven patients
had stable disease, four patients had progressive disease, and
two patients were unevaluable for response. A summary of
the response data is given in Table 3.
Survival
The median overall survival was 15.7 months, (2.5–
41.4 months). The Kaplan-Meier estimate of the distribu-
tion of the overall survival is presented in Figure 1. Forty-
TABLE 1. Patient Characteristics (n  61)
Age
Median 63 (36–84)
Gender
Male 31 (50.8%)
Female 30 (49.2%)
Race
Caucasian 59 (96.7%)
African-American 1 (1.6%)
Other 1 (1.6%)
Performance status
0 26 (42.6%)
1 34 (55.7%)
2 1 (1.6%)
Weight loss in previous 6 mo
None 34 (55.7%)
5% of body weight 11 (18.0%)
5–10% of body weight 10 (16.4%)
10% of body weight 6 (9.8%)
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eight of the 61 eligible patients had died. The 1- and 2-year
survival were 63.9 and 23.8% respectively. The Median PFS
was 8.6 months. The incidence of intrathoracic failure was
24.6%. Figure 2 presents the Kaplan-Meier estimate of the
distribution of PFS.
DISCUSSION
The treatment of limited SCLC has not been favorably
impacted upon since the last intergroup study, published almost
10 years ago, reported a median survival of 23 months and a
5-year survival of 26% for the twice-daily radiotherapy arm.10
Attempts to improve on these results have centered upon two
major therapeutic principles—improving systemic control (che-
motherapy) and/or improving local control (radiotherapy). Pac-
litaxel has been shown to have significant activity as a single
agent in patients with SCLC in phase II trials,26,27 and the
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FIGURE 1. Overall survival.
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FIGURE 2. Progression-free survival.
TABLE 2. Hematologic Toxicity (n  63)
Grade 3 (%) 4 (%)
Hematologic toxicity (n  63)
Leukopenia 46.0 31.7
Granulocytopenia 17.5 61.2
Thrombocytopenia 1.6 6.3
Anemia 14.3 —
Febrile neutropenia 3.2 15.9
Nonhematologic toxicity (n  63)
Hemorrhage 1.6 —
Infection 7.9 —
Fever (no infection) 1.6 —
Nausea 11.1 —
Vomiting 4.8 3.2
Diarrhea 1.6 3.2
Stomatitis 1.6 1.6
Pulmonary 3.2 —
Cardiac 1.6 1.6
Hypotension — 1.6
Alopecia 1.6 —
Neurologic 14.3 —
Metabolic 4.8 3.2
Coagulation 1.6 —
Anorexia 1.6 —
Hyperglycemia 1.6 —
Arthralgia/myalgia 3.2 —
Fatigue 6.3 —
Hyponatremia 1.6 —
Esophagitis 22.2 9.5
Dehydration 4.8 1.6
All other toxicities — 1
TABLE 3. Best Objective Response Summary: 61 Eligible
Patients
Response n (%)
Complete response 12 (19.7)
Partial response 36 (59.0)
No change/stable disease 7 (11.5)
Progressive disease 4 (6.6)
Unevaluable 2 (3.3)
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three-drug combination of paclitaxel, cisplatin and etoposide
seemed promising in phase II trials conducted in patients with
extensive SCLC.28,30,31
Radiation oncologists have proposed the concept that if
the total dose for once-daily radiotherapy was increased, it
could be as effective, or more so, than twice-daily radiother-
apy.25 Given this information, ECOG conducted a phase II
study of the three-drug combination of PET with concurrent
high dose once daily TRT (63 Gy) in patients with LD-SCLC.
Unfortunately, the results were disappointing; with an overall
response rate of 78.7% that included only 19.7% complete
responses. Importantly, the median survival of 15.7 months
and 1- and 2-year survival of 63.9% and 23.8% respectively,
do not compare favorably with two prior trials evaluating this
regimen (Table 4); one with TRT commencing at cycle 3 of
chemotherapy and another at cycle 1. The first study by
Bremnes et al.,38 combined paclitaxel 175 mg/m2 intravenous
with cisplatin 50 mg/m2 intravenous day 1 and etoposide 100
mg/m2 intravenous day 1 and 100 mg oral twice daily days 2
to 5 for 5 cycles in combination with TRT (42 Gy in 15
fractions starting at cycle 3 of chemotherapy) in 39 patients
with LD-SCLC. Overall response rate was 92% and median
survival was 21 months.38 A second study by the Radiation
Therapy Oncology Group found equally favorable results
when they administered paclitaxel 135 mg/m2 intravenous
with cisplatin 60 mg/m2 intravenous day 1 and etoposide 60
mg/m2 intravenous day 1 and 80 mg/m2 days 2 and 3 with
concurrent twice daily TRT (45 Gy in 30 fractions over 3
weeks starting at cycle 1) to 55 patients with LD-SCLC.
Paclitaxel was increased to 175 mg/m2 at cycle 3.39 The
response rate was 92%, median and 1-year survival were 24.7
months and 83% respectively. Similar to these trials we found
grade 3 and 4 neutropenia to be the most common hemato-
logic toxicity seen in three quarter of patients.38,39 We had a
higher incidence of febrile neutropenia occurring in 19% of
patients. Similar to the Radiation Therapy Oncology Group
trial,39 grade 3 and 4 esophagitis was the most common
nonhemtaologic toxicity occurring in approximately one-
third of patients.
There are several potential reasons for the discouraging
results seen in our study. Inferior local control is one such
possibility perhaps due to the use of the postinduction radi-
ation port for the final 18 Gy or the “delayed” concurrent
radiotherapy that was employed starting with the third cycle
of chemotherapy. Several reports suggest early initiation of
TRT, within 4 to 6 weeks of chemotherapy, may be benefi-
cial.43,44 However, the overall local failure rate for patients
was 24.8%. This includes those patients who failed solely
within the radiation port, 16.4%, with an additional 8.4% of
patients who failed either within or outside the radiation field.
This is comparable to the local failure pattern of both arms of
the intergroup study in which the radiotherapy was given
concurrent with the first cycle of chemotherapy.10 In this
study, the overall failure rate was 52% for the once daily arm
and 36% for the twice-daily arm. Therefore, given the low
incidence of local failure seen in this trial it is difficult to
support this premise for the poor outcome seen in this trial.
The lack of adequate systemic control is another pos-
sibility. This may in part be due to the need for reduced
chemotherapy doses given with TRT in cycles 3 and 4 due to
the inability to use filgrastim with concurrent TRT. Although
the cisplatin dose remained the same, the dose of etoposide
was decreased by one-third to accommodate paclitaxel. Ad-
ditionally, the initial enthusiasm for the addition of paclitaxel
to cisplatin and etoposide has waned considerably given the
results of two recently completed randomized trials compar-
ing PE with PET in patients with previously untreated exten-
sive SCLC.33,45 The results of these trials failed to reveal any
improvement in survival for patients treated with PET che-
motherapy. One trial demonstrated increased lethal toxicities
for patients receiving PET. Age70 was found to be a factor
predisposing patients to increased toxicity.45
Another contributing factor could be the high incidence
of CNS only failures seen in this trial. The use of PCI was not
mandated in this trial. Eleven patients (18.6%) suffered with
CNS only relapse. In this trial the majority of patients, 66%,
did not receive PCI. PCI imparts a modest survival advantage
for the patients with SCLC who achieve a CR after combined
modality therapy.14
Given the disappointing results of our trial we conclude
that the combination of PET chemotherapy with delayed
concurrent TRT does not represent an improvement over the
current standard therapy for PE and early concurrent thoracic
radiotherapy. Future directions will include evaluating other
active chemotherapy agents, unique dosing schedules of ra-
diotherapy, and molecularly targeted therapy.
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TABLE 4. Comparison of Trials of PET with TRT in LD-SCLC
Chemotherapy RT n RR OS (months)
E2596 Paclitaxel 170 mg/m2 IV d2 Cisplatin 60 mg/m2 IV d1 Etoposide 80
mg/m2 IV d1–3 Paclitaxel 135 mg/m2 IV d2 c3–4
63 Gy starting cycle 3 61 79% 15.7
Ettinger39 Paclitaxel 135 mg/m2 IV d1 c1–2 Cisplatin 60 mg/m2 IV d1
Etoposide 60 mg/m2 IV d1 Etoposide 80 mg/m2 PO d2–3
Paclitaxel 175 mg/m2 IV c 3–4
45 Gy starting cycle 1 55 92% 24.7
Bremnes38 Paclitaxel 175 mg/m2 IV d1 c1–2 Cisplatin 50 mg/m2 IV d1
Etoposide 100 mg/m2 IV d1 Etoposide 100 mg/m2 PO bid d2–5
42 Gy starting cycle 3 39 92% 21.0
PET, cisplatin plus etoposide plus paclitaxel; TRT, thoracic radiotherapy; OS, overall survival; SCLC, small cell lung cancer; LD, limited stage disease; RR, response rate; RT,
radiotherapy.
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